Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

A Study to Investigate Safety, Tolerability and Pharmacokinetics of VH5356136 in Adult Participants Without HIV

10 septembre 2026 mis à jour par: ViiV Healthcare

A Phase 1, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Parenterally Administered VH5356136 in Adult Participants Without HIV

The study aims to evaluate the safety, tolerability and pharmacokinetic (PK) properties of a single dose of VH5356136 in adult participants without human immunodeficiency virus (HIV). This study will be conducted following the availability of initial safety and PK clinical data from formulation of the parent drug VH4524184.

Aperçu de l'étude

Type d'étude

Interventionnel

Inscription (Estimé)

160

Phase

  • La phase 1

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Coordonnées de l'étude

Sauvegarde des contacts de l'étude

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

  • Adulte

Accepte les volontaires sains

Oui

La description

Inclusion Criteria:

  • Participants must be 18 to 55 years of age inclusive at the time of signing the informed consent form (ICF).
  • Participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.
  • Participants who are able to understand and comply with protocol requirements and timetables, instructions, and protocol-stated restrictions.
  • Body weight ≥50.0 kg (110 lbs) for men and ≥45.0 kg (99 lbs) for women and body mass index within the range 18.5 to 32.0 kg/m^2 (inclusive).
  • Participants of any sex (male or female) are eligible. A female participant (female sex assigned at birth) is eligible to participate if they are a person of non-childbearing potential (PONCBP).
  • Capable of providing signed informed consent, which includes compliance with the requirements and restrictions listed in the ICF and in the protocol.

The criteria presented above represent a subset of the key inclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.

Exclusion Criteria:

  • History or presence of, respiratory, hepatic, renal, gastrointestinal, endocrine, hematologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
  • History of drug hypersensitivity, delayed-type hypersensitivity or severe hypersensitivity reaction or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates study participation.
  • History of or on-going high-risk behaviors that may put the participant at increased risk for HIV acquisition in the opinion of the investigator.
  • Any preexisting physical or mental condition which, in the opinion of the investigator or the medical monitor, may interfere with the participant's ability to comply with the dosing schedule and/or protocol evaluations or which may compromise the safety of the participant.
  • Previous exposure to the parent molecule VH4524184.
  • Past or intended use of over-the-counter or prescription medication within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to dosing and for the duration of the study.
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half-lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study intervention.
  • Participants receiving any protocol-prohibited medication and who are unwilling or unable to switch to an alternate medication.
  • Current enrolment or participation in another clinical study.
  • Any acute laboratory abnormality at screening, which, in the opinion of the investigator, would preclude the participant's participation in the study of an investigational compound.
  • Positive HIV antibody/antigen test.
  • History of clinically relevant hepatitis within the last 6 months.
  • Positive hepatitis B or hepatitis C test.
  • Clinically significant cardiovascular disease..
  • QT interval corrected for heart rate according to Fridericia's formula (QTcF) >450 milliseconds (msec) and >480 msec (bundle branch block).
  • Blood pressure (BP) >140/90 (systolic BP/diastolic BP [SBP/DBP]).
  • Resting heart rate (HR) <50 or >100 beats per minute (bpm) when vital signs are measured at Screening or Check-in.

The criteria presented above represent a subset of the key exclusion criteria for the study. Additional criteria, restrictions, and eligibility requirements may apply as specified in the study protocol.

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: Randomisé
  • Modèle interventionnel: Affectation parallèle
  • Masquage: Tripler

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: VH5356136 Formulation 1
Participants will receive a single dose of VH5356136 Formulation 1 administered on Day 1.
Participants will receive VH5356136 Formulation 1 on Day 1.
Comparateur placebo: Placebo for VH5356136 Formulation 1
Participants will receive a single dose of placebo for VH5356136 Formulation 1 administered on Day 1.
Participants will receive placebo for VH5356136 Formulation 1 on Day 1.
Expérimental: VH5356136 Formulation 2
Participants will receive a single dose of VH5356136 Formulation 2 administered on Day 1.
Participants will receive VH5356136 Formulation 2 on Day 1.
Comparateur placebo: Placebo for VH5356136 Formulation 2
Participants will receive a single dose of placebo for VH5356136 Formulation 2 administered on Day 1.
Participants will receive placebo for VH5356136 Formulation 2 on Day 1.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of participants with drug-related adverse events (AEs)
Délai: From Day 1 to Month 18
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. A drug-related AE is an AE that, in the opinion of the investigator, is related to one of the study interventions.
From Day 1 to Month 18
Number of participants with Grade 2 to Grade 5 AEs
Délai: From Day 1 to Month 18
The grading of AEs is performed based on the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading scale, here Grade 2 = moderate, Grade 3=severe, Grade 4 = potentially life-threatening, Grade 5 = death.
From Day 1 to Month 18
Number of participants with serious adverse events (SAEs)
Délai: From Day 1 to Month 18
An SAE is defined as any untoward medical occurrence that results in death, are life threatening, require hospitalization or prolongation of hospitalization or results in disability/incapacity, is a congenital anomaly/birth defect in the offspring of a study participant, is considered or defined as an important medical event, or abnormal pregnancy outcomes.
From Day 1 to Month 18
Area under the concentration time curve from zero (pre-dose) to the last quantifiable concentration (post dose) (AUC[0-tlast]) for VH5356136
Délai: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
AUC(0-tlast) for VH4524184
Délai: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Maximum plasma concentration (Cmax) for VH5356136
Délai: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Cmax for VH4524184
Délai: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Time to maximum observed plasma drug concentration (tmax) for VH5356136
Délai: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Tmax for VH4524184
Délai: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
Terminal half-life (t1/2) for VH5356136
Délai: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose
t1/2 for VH4524184
Délai: From Day 1 (pre-dose) up to Month 18 post-dose
From Day 1 (pre-dose) up to Month 18 post-dose

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Number of participants with Grade 3 and Grade 4 laboratory abnormalities
Délai: From Day 1 (pre-dose) up to Month 18 post-dose
The laboratory abnormalities are assessed using the DAIDS grading scale, where Grade 3 = severe and Grade 4 = potentially life-threatening.
From Day 1 (pre-dose) up to Month 18 post-dose

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Estimé)

6 novembre 2026

Achèvement primaire (Estimé)

9 mai 2029

Achèvement de l'étude (Estimé)

9 mai 2029

Dates d'inscription aux études

Première soumission

10 septembre 2026

Première soumission répondant aux critères de contrôle qualité

10 septembre 2026

Première publication (Réel)

16 septembre 2026

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

16 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

10 septembre 2026

Dernière vérification

1 septembre 2026

Plus d'information

Termes liés à cette étude

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

OUI

Description du régime IPD

Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.viiv-studyregister.com/documents/About_ViiV_Patient_Level_Data_Sharing_Final_28May2026.pdf

Délai de partage IPD

Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Critères d'accès au partage IPD

Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Type d'informations de prise en charge du partage d'IPD

  • PROTOCOLE D'ÉTUDE
  • SÈVE
  • CIF
  • RSE

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner